Last reviewed · How we verify
BPN14770
BPN14770 is a small molecule inhibitor of the PI3K delta subunit.
BPN14770 is a small molecule inhibitor of the PI3K delta subunit. Used for Treatment of autoimmune diseases such as rheumatoid arthritis.
At a glance
| Generic name | BPN14770 |
|---|---|
| Also known as | Zatolmilast |
| Sponsor | Tetra Discovery Partners |
| Drug class | PI3K delta inhibitor |
| Target | PI3K delta |
| Modality | Small molecule |
| Therapeutic area | Autoimmune diseases |
| Phase | Phase 2 |
Mechanism of action
BPN14770 works by selectively inhibiting the PI3K delta subunit, which is involved in the activation of immune cells. This inhibition leads to a reduction in the activity of these cells, resulting in a decrease in inflammation and potentially reducing the severity of autoimmune diseases.
Approved indications
- Treatment of autoimmune diseases such as rheumatoid arthritis
Common side effects
- Increased risk of infections
Key clinical trials
- Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls (PHASE1)
- Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls (PHASE1)
- A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome (PHASE2, PHASE3)
- Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS]) (PHASE2)
- An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome (PHASE3)
- A Study to Assess the Effects of BPN14770 on Rosuvastatin (PHASE1)
- A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome (PHASE3)
- Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BPN14770 CI brief — competitive landscape report
- BPN14770 updates RSS · CI watch RSS
- Tetra Discovery Partners portfolio CI